REGENERON: Tapping Other TRAPS in 3Q12 - ZALTRAP and ARCALYST!
While EYLEA’s (VEGF Trap-Eye, L in US, partnered with Bayer for Ex-US, wet AMD) launch skyrocketed Regeneron (REGN); we expect other TRAP based products in the pipeline to sustain this trajectory in 2012! Recently, REGN and its partner, Sanofi granted A Priority Review for ZALTRAP (VEGF trap/ aflibercept, R, mCRC – 2nd-line; PhII/III, mCRC – 1st-line, NSCLC, prostate; PDUFA: Aug. 4, 2012) in combination with the irinotecan-fluoropyrimidine-based chemotherapy in metastatic colorectal cancer (mCRC) pts who were previously treated with an oxaliplatin-containing regimen, which was a pleasant surprise! In the current competitive scenario, we have assigned risk-ownership adjusted peak sales of… For more details, please read our report released on April 5, 2012 on REGN, titled “Tapping Other TRAPS in 3Q12 - ZALTRAP and ARCALYST!”
COMPANIES MENTIONED
REGENERON
REGENERON
More Publications
REGENERON, Outperform - Is Trap Safer? Rilonacept vs. NVS’ Ilaris in Gout
US$ 90.00
June 2011
5 pages
REGENERON - A Myriad of Opportunities - EYLEA (AMD, CRVO) + ZALTRAP (mCRC) + ARCALYST (Gout)
US$ 140.00
April 2012
6 pages
Regeneron - Entering the Commercial TRAP
US$ 140.00
July 2011
7 pages
Regeneron Pharmaceuticals, Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
US$ 499.00
September 2026
50 pages
